Syndax Pharmaceuticals Equity 2024

Syndax Pharmaceuticals Aktienanalyse

What does Syndax Pharmaceuticals do?

Syndax Pharmaceuticals Inc. is a biotechnology company based in Waltham, Massachusetts that focuses on the development of novel therapeutics for cancer and immune disorders. The company was founded in 2005 by Arlene Morris and has been listed on NASDAQ since 2014. Business model and product pipeline: Syndax develops small molecules that are capable of modulating epigenetic changes in cells. This approach is based on the understanding that cancer cells often have genetic alterations that result in changes in gene expression. By modulating such epigenetic changes, cancer cells can function normally again, which can help stop or inhibit the growth of cancer cells. The company's product pipeline includes several drugs that are being developed in various stages of clinical research. One of the most advanced programs is E2112, an orally administered drug targeting breast cancer. The drug is currently in Phase III studies that are investigating the efficacy and safety of the drug in combination with other standard therapies. Another promising program is SNDX-6352, an anti-CSF-1 receptor antibody being developed for the treatment of various types of cancer, including certain solid tumors and hematologic malignancies. The drug has been successfully tested in Phase Ib studies, and the company is currently planning to evaluate it in further clinical trials. In addition to cancer research, Syndax is also working on the development of therapeutics for various inflammatory and immunologic diseases. The company is working on a program for the treatment of idiopathic pulmonary fibrosis and also a program for the treatment of thrombotic thrombocytopenic purpura (TTP), a rare blood disorder. In addition to internally developed drugs, the company is collaborating with other biotechnology and pharmaceutical companies to explore innovative treatment options for other diseases. The company has entered into a partnership with Japanese company Kyowa Hakko Kirin Co. Ltd. to develop and market the SNDX-6352 program. Current developments: Syndax has recently experienced strong growth and is investing significantly in research and development to expand its pipeline and expand its drugs. The company recently completed a financing round that raised $80 million to advance its development projects. A key milestone for the company was the appointment of Briggs W. Morrison as CEO in 2020. Morrison, an experienced pharmaceutical manager, was previously the Chief Executive Officer and President of Syndax until 2016. He is now returning to the company and leading efforts to develop innovative therapeutics. Morrison has previously worked at Pfizer and AstraZeneca, bringing valuable experience in the development and marketing of new drugs. Summary: Syndax Pharmaceuticals Inc. is a biotechnology company that focuses on the development of drugs for cancer and inflammatory diseases. The company has a promising product pipeline that includes several therapeutics in various stages of development, including E2112 and SNDX-6352. Syndax recently completed a strong financing round and plans to continue its research and development efforts to discover and develop new innovative therapeutics. Syndax Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Syndax Pharmaceuticals's Equity

Syndax Pharmaceuticals's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Syndax Pharmaceuticals's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Syndax Pharmaceuticals's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Syndax Pharmaceuticals's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Syndax Pharmaceuticals’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Syndax Pharmaceuticals stock

What is the equity of Syndax Pharmaceuticals this year?

Syndax Pharmaceuticals has equity of 554.2 M USD this year.

What was the equity of Syndax Pharmaceuticals compared to the previous year?

The equity of Syndax Pharmaceuticals has increased/decreased by 18.57% increased compared to the previous year.

What impact does a high equity have on investors of Syndax Pharmaceuticals?

A high equity is advantageous for investors of Syndax Pharmaceuticals as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Syndax Pharmaceuticals?

A low equity can be a risk for investors of Syndax Pharmaceuticals, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Syndax Pharmaceuticals affect the company?

An increase in equity of Syndax Pharmaceuticals can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Syndax Pharmaceuticals affect the company?

A reduction in equity of Syndax Pharmaceuticals can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Syndax Pharmaceuticals?

Some factors that can affect the equity of Syndax Pharmaceuticals include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Syndax Pharmaceuticals so important for investors?

The equity of Syndax Pharmaceuticals is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Syndax Pharmaceuticals take to change the equity?

To change equity, Syndax Pharmaceuticals can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Syndax Pharmaceuticals pay?

Over the past 12 months, Syndax Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Syndax Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Syndax Pharmaceuticals?

The current dividend yield of Syndax Pharmaceuticals is .

When does Syndax Pharmaceuticals pay dividends?

Syndax Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Syndax Pharmaceuticals?

Syndax Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Syndax Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Syndax Pharmaceuticals located?

Syndax Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Syndax Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Syndax Pharmaceuticals from 10/4/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/4/2024.

When did Syndax Pharmaceuticals pay the last dividend?

The last dividend was paid out on 10/4/2024.

What was the dividend of Syndax Pharmaceuticals in the year 2023?

In the year 2023, Syndax Pharmaceuticals distributed 0 USD as dividends.

In which currency does Syndax Pharmaceuticals pay out the dividend?

The dividends of Syndax Pharmaceuticals are distributed in USD.